Moleculin preclinical data links Annamycin to immune response in pancreatic cancer
Moleculin Biotech, Inc. (Nasdaq: MBRX) presented preclinical data at the AACR Conference on Pancreatic Cancer in San Diego suggesting that ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)